EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access · CC BY-NC-ND 4.0

Comparative Effectiveness of Nivolumab and Ipilimumab Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy in PD-L1 Negative Metastatic Non-Small Cell Lung Cancer Patients

Marjon V Verschueren, Dagmar T A Hiensch, Peter M J Plomp, Lisanne A Kastelijn, Ewoudt M W van de Garde, Bas J M Peters

Clinical Lung Cancer · 2025

DOI: 10.1016/j.cllc.2025.01.009 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Clinical Lung Cancer, 2025. Verfasst von Marjon V Verschueren und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacy, St. Antonius Hospital, Utrecht Nieuwegein, The Netherlands; Division of Pharmacoepidemiology and Clinical Pharmacolo…. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Antibodies, Monoclonal, Humanized, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 9 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Recently, the combination of nivolumab, ipilimumab and chemotherapy (NIC) became available for the treatment of metastatic non-small cell lung cancer (mNSCLC) patients, introducing a new treatment option. This study aimed to compare the treatment response and real-world outcomes of NIC with the current standard of care pembrolizumab plus chemotherapy (PC) in PD-L1 negative mNSCLC patients treated in clinical practice and to compare these outcomes with the results of the Checkmate-9LA trial. METHODS: All mNSCLC patients with PD-L1

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsAntibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsNivolumabIpilimumabHumansMaleFemaleMiddle AgedB7-H1 AntigenAgedAdultRetrospective StudiesSurvival RateFollow-Up StudiesPrognosisAged, 80 and overTreatment Outcome

Stichwörter der Autor:innen

Anti-cancer treatmentsEarly effectivenessObservational studyReal-world evidenceReal-world outcomes

Substanzen

Antibodies, Monoclonal, HumanizedB7-H1 AntigenNivolumabCD274 protein, humanIpilimumabpembrolizumab

Autor:innen und Institutionen

  • Department of Clinical Pharmacy, St. Antonius Hospital, Utrecht Nieuwegein, The Netherlands; Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University,…
  • Department of Clinical Pharmacy, St. Antonius Hospital, Utrecht Nieuwegein, The Netherlands.
  • Pulmonology Department, Isala Hospital, Zwolle, The Netherlands.
  • Pulmonology Department, St. Antonius Hospital, Utrecht Nieuwegein, The Netherlands.

Zitieren

APA

Verschueren, M. V., Hiensch, D. T. A., Plomp, P. M. J., Kastelijn, L. A., van de Garde, E. M. W., & Peters, B. J. M. (2025). Comparative Effectiveness of Nivolumab and Ipilimumab Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy in PD-L1 Negative Metastatic Non-Small Cell Lung Cancer Patients. Clinical Lung Cancer. https://doi.org/10.1016/j.cllc.2025.01.009

Vancouver

Verschueren MV, Hiensch DTA, Plomp PMJ, Kastelijn LA, van de Garde EMW, Peters BJM. Comparative Effectiveness of Nivolumab and Ipilimumab Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy in PD-L1 Negative Metastatic Non-Small Cell Lung Cancer Patients. Clinical Lung Cancer. 2025. doi:10.1016/j.cllc.2025.01.009

BibTeX
@article{Verschueren2025,
  author = {Verschueren, Marjon V and Hiensch, Dagmar T A and Plomp, Peter M J and Kastelijn, Lisanne A and van de Garde, Ewoudt M W and Peters, Bas J M},
  title = {Comparative Effectiveness of Nivolumab and Ipilimumab Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy in PD-L1 Negative Metastatic Non-Small Cell Lung Cancer Patients},
  journal = {Clinical Lung Cancer},
  year = {2025},
  doi = {10.1016/j.cllc.2025.01.009}
}
Kostenlos starten →